中文

Product Pipeline

Putanning® R&D Pipeline

Putanning®
——Meloxicam Injection (II)

Drug Information
Generic Name:Meloxicam Injection (Ⅱ)
Chinese Brand Name: Putanning®
U.S. Brand Name:QAMZOVA ™
Indication: For postoperative pain management in adults. When used in combination with opioids, it can help reduce opioid consumption.

Development and Approval
Developed using the company's proprietary solubilization technology platform, the product was simultaneously approved in China and the U.S. in April 2025. It is China's first 24-hour long-acting, once-daily NSAID injection for postoperative pain and the first 2.2-class new postoperative analgesic drug approved in the country.

R&D Pipeline

Building the strongest international pain management product line

  • Application Areas
  • Product
  • Mechanisms of Action
  • Dosage Forms
  • Indications
  • Preclinical
  • IND
  • PhaseⅠ
  • Phase Ⅱ
  • Phase Ⅲ
  • NDA
  • Approved
QP001
COX-2
Injection
Postoperative pain

China's first 24-hour long-acting analgesic

Perioperative pain

QP002
Fixed-combination local anesthetic
long-acting injectio
Postoperative pain

China's first 3-day long-acting fixed combination local anesthetic administered using a novel instillation method

QP-6211
single-entity local anesthetic
long-acting injection
Postoperative pain

World's first 1-week extended-release ropivacaine formulation for nerve block or local infiltration

chronic pain

QP-5113
TRPV-1
topical formulations
peripheral neuropathic pain

China's first 3-month ultra-long-acting topical formulation for neuropathic pain

Swipe right to see more

Search
X